Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Study:

Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Rationale:

Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Pemetrexed disodium may stop the growth of tumor cells by blocking some enzymes needed for cell growth. It is not yet known whether giving bevacizumab or pemetrexed disodium alone or in combination is more effective in treating non-squamous non-small cell lung cancer.

Purpose:

This randomized phase III trial is studying bevacizumab and pemetrexed disodium alone or in combination after induction therapy to see how well they work in treating patients with advanced non-squamous non-small cell lung cancer.

Study Status: Recruiting

Recruiting:
Clinical Trials Office - Cleveland Clinic Florida - Weston 954-659-5705

Anjali S. Advani 216-839-3200

Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100

Clinical Trials Office - Cleveland Clinic Cancer Center at Fai 216-476-9362

Anjali S. Advani 216-524-7979

Anjali S. Advani 440-878-2500

Clinical Trials Office - Cleveland Clinic - Wooster 800-862-7798

Condition Intervention Phase
Lung Cancer Biological: bevacizumab
Drug: pemetrexed disodium
Phase 3

Verified by Eastern Cooperative Oncology Group December, 2012

Sponsored by: Eastern Cooperative Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT01107626

Study Type: Interventional

Study Design: Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Florida - Weston
Weston, Florida 33331
United States

Cleveland Clinic Beachwood Family Health and Surgery Center
Beachwood, Ohio 44122
United States

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States

Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States

Cleveland Clinic Foundation - Strongsville
Strongsville, Ohio 44136
United States

Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States

Suresh Ramalingam, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site